Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH – Get Rating) (TSE:AUP) shot up 7.1% during trading on Wednesday . The stock traded as high as $4.98 and last traded at $4.98. 24,215 shares were traded during mid-day trading, a decline of 99% from the average session volume of 3,438,562 shares. The stock had previously closed at $4.65.
Wall Street Analyst Weigh In
A number of equities research analysts have issued reports on AUPH shares. Royal Bank of Canada cut their price target on Aurinia Pharmaceuticals from $18.00 to $10.00 and set an “outperform” rating for the company in a research note on Friday, November 4th. StockNews.com started coverage on Aurinia Pharmaceuticals in a research note on Wednesday, October 12th. They set a “hold” rating for the company. Oppenheimer downgraded Aurinia Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Friday, November 4th. HC Wainwright cut their price target on Aurinia Pharmaceuticals from $26.00 to $14.00 and set a “buy” rating for the company in a research note on Monday, November 7th. Finally, SVB Leerink cut their price target on Aurinia Pharmaceuticals from $17.00 to $12.00 and set an “outperform” rating for the company in a research note on Friday, November 4th. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $12.25.
Aurinia Pharmaceuticals Stock Performance
The stock has a 50-day moving average price of $6.71 and a two-hundred day moving average price of $8.73.
Institutional Inflows and Outflows
Aurinia Pharmaceuticals Company Profile
Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis.
- Get a free copy of the StockNews.com research report on Aurinia Pharmaceuticals (AUPH)
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Is the 60/40 Portfolio Mix Still in Vogue?
- Institutional Support for Analog Devices Remains High
- Three CBD Stocks to Dominate a Budding Industry
- Microsoft Shares: Is it Time to Back Up the Truck?
Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.